Metformin and improvement of the hepatic insulin resistance index independent of anthropometric changes

Endocrine Practice

Volumn 18, Issue 1, 2012, Pages 8-16

  Gómez Sámano, Miguel Ángel ^a   Gulias Herrero, Alfonso ^a   Cuevas Ramos, Daniel ^a   Brau Figueroa, Hasan ^a   Mehta, Roopa ^a   Vargas Gutiérrez, Diana ^a   Meza Arana, Clara ^a   Nieves Niebla, Jazmín María ^a   Vázquez Hernández, María Olivia ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; METFORMIN;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE INTOLERANCE; HEPATIC INSULIN RESISTANCE INDEX; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MEXICO; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; ANTHROPOMETRY; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPIDS; LIVER; LONGITUDINAL STUDIES; MALE; METFORMIN; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; WAIST CIRCUMFERENCE;

EID: 84857521073     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11072.OR     Document Type: Article

References (29)

1. American Diabetes Association. Standards of medical care in diabetes 2010 [Erratum in Diabetes Care. 2010;33:692]. Diabetes Care. 2010;33(Suppl 1):S11-S61.
2. Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest. 2006;116:1756-1760.
3. Choukem SP, Sobngwi E, Fetita LS, et al. Multitissue insulin resistance despite near-normoglycemic remission in Africans with ketosis-prone diabetes. Diabetes Care. 2008; 31:2332-2337.
4. Groop LC, Bonadonna RC, DelPrato S, et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest. 1989;84:205-213.
5. Mitrakou A, Kelley D, Veneman T, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes. 1990;39: 1381-1390.
6. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006; 55:1430-1435.
7. Bastarrache Raúl, Laviada-Molina Hugo, Vázquez- Sánchez Cuauhtémoc. Análisis crítico de los nuevos crite-rios que sustentan el diagnóstico de pre-diabetes. Revista de Endocrinología y Nutrición (Mex). 2004;12:90-96.
8. Cherrington AD, Edgerton D, Sindelar DK. The direct and indirect effects of insulin on hepatic glucose production in vivo. Diabetologia. 1998;41:987-996.
9. Girard J. Insulin's effect on the liver: "direct or indirect?" continues to be the question. J Clin Invest. 2006;116: 302-304.
10. Choukem SP, Gautier JF. How to measure hepatic insulin resistance? Diabetes Metab. 2008;34:664-673.
11. Adrogué HJ. Glucose homeostasis and the kidney. Kidney Int. 1992;42:1266-1282.
12. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care. 2007;30:89-94.
13. Liang L, Fu JF, Zou CC, Hong F, Wang CL, Wang XM. Metformin hydrochloride ameliorates adiponectin levels and insulin sensitivity in adolescents with metabolic syndrome. Zhonghua Er Ke Za Zhi. 2006;44:118-121.
14. Kautzky-Willer A, Tura A, Winzer C, et al. Insulin sensi-tivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedi-one. Diabetes Obes Metab. 2006;8:561-567.
15. Bruce S, Park JS, Fiedorek FT, Howlett HC. Beta-cell response to metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes. Int J Clin Pract. 2006;60:783-790.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis Model Assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
18. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999; 22:1462-1470.
19. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II dia-betes mellitus. N Engl J Med. 1998;338:867-872.
20. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent dia-betic subjects. J Clin Endocrinol Metab. 1991;73: 1294-1301.
21. Nosadini R, Avogaro A, Trevisan R, et al. Effect of metfor-min on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care. 1987;10:62-67.
22. Johnson AB, Webster JM, Sum CF, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II dia-betic patients. Metabolism. 1993;42:1217-1222.
23. Perriello G, Misericordia P, Volpi E, et al. Acute antihyper-glycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 1994;43:920-928.
24. Widén EI, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant nor-moglycemic first-degree relatives of patients with NIDDM. Diabetes. 1992;41:354-358.
25. Jani R, Molina M, Matsuda M, et al. Decreased non-insu-lin-dependent glucose clearance contributes to the rise in fast-ing plasma glucose in the nondiabetic range. Diabetes Care. 2008;31:311-315.
26. Preiss D, Sattar N, Harborne L, Norman J, Fleming R. The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. Int J Clin Pract. 2008;62:1337-1343.
27. Krakoff J, Clark JM, Crandall JP, et al; Diabetes Prevention Program Research Group. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring). 2010;18:1762-1767.
28. Barskova VG, Eliseev MS, Kudaeva FM, et al. Effect of metformin on the clinical course of gout and insulin resistance [Article in Russian]. Klin Med (Mosk). 2009;87: 41-46.
29. Eguchi K, Tomizawa H, Ishikawa J, et al. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose toler-ance and early diabetes. Hypertens Res. 2007;30: 23-30.